Why insider trading matters?

If management teams do not own any relevant stakes in the companies they guide, they may not be focused on creating wealth for shareholders to the same degree, compared to those that see their personal wealth increase when share prices rise.

- Klaus Gugler, Economist
CRISPR Therapeutics AG (CRSP)
Sector: Healthcare; Industry: Biotechnology

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious human diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. Further, it engages in developing regenerative medicine programs in diabetes; and in vivo and other genetic disease programs to treat glycogen storage disease Ia, Duchenne muscular dystrophy, and cystic fibrosis. The company has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland.


Trade Date Insider Title Buy/Sell #Shares Price Value Option
2021-03-23 Klein Lawrence Otto CBO & COO Sell 100,000 $128.05 $12,805,240 Yes
2021-03-22 Bolzon Bradley J PhD Director Sell 30,374 $132.37 $4,020,667 No
2021-02-19 Bolzon Bradley J PhD Director Sell 171,003 $149.11 $25,497,840 No
2021-01-15 Kulkarni Samarth Chief Executive Officer Sell 20,000 $213.67 $4,273,311 Yes
2021-01-15 Klein Lawrence Otto CBO & COO Sell 25,000 $215.20 $5,379,940 Yes
2021-01-19 KASINGER JAMES R. General Counsel and Secretary Sell 27,500 $204.94 $5,635,944 Yes
2020-12-21 Ho Tony W Executive VP, Head of R&D Sell 23,551 $149.23 $3,514,610 Yes
2020-12-16 Bolzon Bradley J PhD Director Sell 15,000 $148.95 $2,234,266 No
2020-12-10 Bolzon Bradley J PhD Director Sell 33,000 $143.35 $4,730,448 No
2020-12-10 Bolzon Bradley J PhD Director Sell 33,000 $143.35 $4,730,448 No
2020-12-10 Kulkarni Samarth Chief Executive Officer Sell 20,000 $142.29 $2,845,782 Yes
2020-12-07 Bolzon Bradley J PhD Director Sell 171,004 $154.53 $26,424,505 No
2020-11-30 Novak Rodger President Sell 100,000 $125.00 $12,500,000 Yes
2020-10-09 Novak Rodger President Sell 25,000 $100.00 $2,500,000 Yes
2020-09-18 Bolzon Bradley J PhD Director Sell 3,035 $86.87 $263,636 No
2020-09-16 Bolzon Bradley J PhD Director Sell 8,965 $86.98 $779,777 No
2020-09-14 Bolzon Bradley J PhD Director Sell 1,155 $84.89 $98,045 No
2020-09-10 Bolzon Bradley J PhD Director Sell 22,845 $85.36 $1,949,996 No
2020-09-01 Bolzon Bradley J PhD Director Sell 60,000 $92.51 $5,550,644 Yes
2020-09-01 TOMSICEK MICHAEL JOHN Chief Financial Officer Sell 12,000 $92.26 $1,107,068 Yes
2020-09-01 Novak Rodger President Sell 25,000 $92.62 $2,315,578 Yes
2020-08-19 Novak Rodger President Sell 25,000 $100.00 $2,500,000 Yes
2020-08-03 TOMSICEK MICHAEL JOHN Chief Financial Officer Sell 12,000 $86.74 $1,040,919 Yes
2020-07-07 Novak Rodger President Sell 25,000 $90.00 $2,250,000 Yes
2020-07-06 Bolzon Bradley J PhD Director Sell 20,000 $82.39 $1,647,730 No
2020-07-01 Novak Rodger President Sell 50,000 $80.00 $4,000,000 No
2020-06-25 Klein Lawrence Otto CBO & COO Sell 70,000 $75.88 $5,311,564 Yes
2020-06-23 Novak Rodger President Sell 50,000 $75.00 $3,750,000 No
2020-06-23 Bolzon Bradley J PhD Director Sell 20,000 $73.93 $1,478,522 No
2020-06-23 Ho Tony W Executive VP, Head of R&D Sell 7,158 $75.04 $537,123 No

Insider Smart

Enphase Energy, Inc (ENPH) - ENPH was $10+ in 15Q1 then dropped to $2 and eventually went under $1. From 15Q4 to 17Q4 it built a 2-year-long base then BOOM! Stock went as high as $70 and likely will make a new high. Catch one or two moves like this you can retire early. One hint before the big move was that CEO and CFO were constantly accumulating, this kind of information is priceless.

Insider Smart

Altimmune, Inc. (ALT) - Venrock Healthcare Capital Partners III, L.P., 10%-owner of ALT bought 1.3M shares in late May then added another 1.5M shares in June with an averaged ~$8 per share. 10 days after the accumulation, ALT price jumped to $10.